SCHEMBL4057734

SCHEMBL4057734

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)OCc1ccccc1

nearest known ligand 0.83

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ACE P12821 16/20 0.83
ABCB11 O95342 2/20 0.83
PDE3A Q14432 1/20 0.68
LMNA P02545 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682457 1.00 ACE (0.83) ACEABCB11PDE3ALMNASMN1; SMN2
SCHEMBL5981613 1.00 ACE (0.83) ACEABCB11PDE3ALMNASMN1; SMN2
Maleic Acid SCHEMBL4191053 0.96 ACE (0.77) ACEABCB11PDE3ALMNASMN1; SMN2
SCHEMBL682458 0.94 ACE (0.75) ACEABCB11PDE3ALMNASMN1; SMN2
SCHEMBL683253 0.93 ACE (0.79) ACEABCB11PDE3A
SCHEMBL16364866 0.93 ACE (0.86) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL994608 0.91 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL11294979 0.91 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL9094436 0.91 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2
Quinapril SCHEMBL19361887 0.91 ACE (1.00) ACEABCB11PDE3ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572661-B1 CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME LUPIN LTD (IN) 2007-04-25 EP claimed
WO-2009113081-A1 TRIS (HYDROXYMETHYL ) AMINO METHANE SALT OF QUINAPRIL AND RAMIPRIL LUPIN LIMITED (IN) 2009-09-17 WO disclosed
US-7482361-B2 Crystalline form for quinapril hydrochloride and process for preparing the same LUPIN LIMITED (IN) 2009-01-27 US disclosed
EP-1572661-B1 CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME LUPIN LTD (IN) 2007-04-25 EP disclosed
EP-1611106-B1 PREPARATION OF QUINAPRIL HYDROCHLORIDE WARNER LAMBERT CO (US) 2006-09-20 EP disclosed
US-20060058347-A1 Crystalline form for quinapril hydrochloride and process for preparing the same LUPIN LIMITED (IN) 2006-03-16 US disclosed
EP-1572661-A1 CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME Lupin Limited (IN) 2005-09-14 EP disclosed
US-6858735-B2 Preparation of quinapril hydrochloride WARNER-LAMBERT COMPANY LLC (US) 2005-02-22 US disclosed
WO-2005010028-A1 ALPHA-AMINO ACID BENZOTHIAZOLYLTHIO ESTER AS INTERMEDIATES FOR MANUFACTURE OF ACE INHIBITORS AND PROCESS FOR PREPARATION THEREOF LUPIN LIMITED (IN) 2005-02-03 WO disclosed
WO-2004087671-A1 PREPARATION OF QUINAPRIL HYDROCHLORIDE WARNER-LAMBERT COMPANY LLC (US) 2004-10-14 WO disclosed
US-20040192613-A1 PREPARATION OF QUINAPRIL HYDROCHLORIDE JENNINGS SANDRA MARIE (US) 2004-09-30 US disclosed
WO-2004054980-A1 CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME LUPIN LIMITED (IN) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058347-A1 Crystalline form for quinapril hydrochloride and process for preparing the same ADH1C, NPPA, ADH1A ACE 14/4885ABCB11 3360/4885PDE3A 43/4885
US-20040192613-A1 PREPARATION OF QUINAPRIL HYDROCHLORIDE PEPD, UBE2L6, GABRD ACE 9/4885ABCB11 1555/4885PDE3A 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.